View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Analysis
August 12, 2020updated 03 Aug 2020 12:43pm

Selva raises $3m to develop novel antiviral against Covid-19

Selva is planning to use the $3m it has raised in a Series A round to support the early clinical development of its lead candidate SLV213 for Covid-19. SLV213 is an antiviral that acts against human, rather than viral, proteases, meaning it differs from most other antivirals in the pipeline for Covid-19. How could combining different types of antivirals help tackle the ongoing pandemic?

By Allie Nawrat

California-based Selva Therapeutics has closed a Series A round with $3m raised. The funding for the round came from private investors, including Board of Directors member Kenneth Kelley; other participants of the round were not disclosed.

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

The proceeds of the Series A will be used to advance Selva’s lead candidate, SLV213, into clinical trials for Covid-19.

The company’s CEO Ted Daley explains that it is currently completing pre-clinical studies of SLV213, but this funding will allow Selva to “open an IND [investigational new drug] application, and start manufacturing of the clinical drug supply” before processing into a Phase I clinical in the third quarter of this year.

Selva, SLV213 and Covid-19

Since licensing SLV213 from University of California San Diego (UCSD), Selva has been developing the drug as an anti-parasitic for Chagas disease. This is because this parasitic disease is a growing threat to the US; although “Chagas disease is endemic to South and Central America, it is staring to expand into the US”, explains Daley.

However, in March, Selva’s academic collaborator at UC San Diego, Dr James McKerrow, “shared data [on SLV213] that he and some colleagues have generated showing very high potency against SARS CoV-2 [the virus which causes Covid-19] in in vitro studies”. As a result, Daley notes, Selva shifted its focus to Covid-19 to meet this urgent priority in global public health.

The reason SLV213 is effective in both Chagas disease and Covid-19 – as well as other coronaviruses, and Nipah and Ebola – is due to its novel mechanism of action. “SLV213 is a small molecule cysteine protease inhibitor”, which particularly targets one class of human proteases, called cathepsins. These “play a role in cleaving the spike protein, which enables SARS-CoV-2 virus to enter the human cell where it reproduces”, explains Daley. Therefore, by inhibiting human cathepsins, SLV213 can prevent viral entry and reproduction, which ultimately causes Covid-19.

This viral entry mechanism is shared by other viruses and makes SLV213 a broad-spectrum antiviral. The mechanism of acting on human, rather than viral, proteases means SLV213 also differs from many of other antiviral drugs being developed against Covid-19. These are known as direct-acting antivirals as they focus on inhibiting viral proteins and proteases – examples include remdesivir and sofosbuvir.

Daley argues that a broad-spectrum antiviral that acts on a host protein could mean SLV213 is “less susceptible to viral resistance” than antivirals targeting the virus. Daley explains that “it would not be to the virus’s benefit to mutate in a way that it no longer engages the cathepsin proteins” to allow entry into the cell. Therefore, “as the SARS CoV-2 virus mutates, it’s reasonable to expect that this particular mechanism and [cell entry] pathway will remain in place”.

Its novel mechanism also means Selva is planning to study SLV213 in moderately symptomatic or asymptomatic patients initially. This an important patient group because, Daley notes, “as this pandemic progresses and more and more people are being tested and diagnosed at earlier stages of the disease, there is a need for treatments for these patients”, primarily to slow or inhibit the progression of the infection and disease. It is also possible that SLV213 could have potential as a prophylactic treatment for Covid-19.

The need for combination therapies for Covid-19

Daley is very clear that both broad spectrum and direct acting antivirals have a role to play in fighting Covid-19.

“For a lot of viral diseases, there’s often not just one single treatment for all patients. Often there is more of a cocktail approach to treating viral diseases”, notes Daley. Human immunodeficiency virus is a notable example of this. “We think that is likely to be the case for SARS-CoV-2 as well”.

Selva believes that SLV213 would be a good candidate to combine with direct acting antivirals because “ours is the only cysteine protease inhibitor being advanced into clinical development for Covid-19”. However, direct acting antivirals would enable the inhibiting of virus replication itself which is important for “viruses that do make it into the cell.”

“There’s going to be a need for cocktail of treatments to address this disease while we’re waiting for widespread availability and administration of the vaccine. Our drug has a chance to be a really critical part of that treatment regimen”, concludes Daley.

Related Companies

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

Verdict deals analysis methodology

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology